CN103721102A - Chinese patent medicine for treating vascular dementia and preparation method thereof - Google Patents
Chinese patent medicine for treating vascular dementia and preparation method thereof Download PDFInfo
- Publication number
- CN103721102A CN103721102A CN201310734509.4A CN201310734509A CN103721102A CN 103721102 A CN103721102 A CN 103721102A CN 201310734509 A CN201310734509 A CN 201310734509A CN 103721102 A CN103721102 A CN 103721102A
- Authority
- CN
- China
- Prior art keywords
- parts
- vascular dementia
- extraction
- treatment
- cornus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 201000004810 Vascular dementia Diseases 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 61
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 241000209020 Cornus Species 0.000 claims abstract 6
- 241001061264 Astragalus Species 0.000 claims abstract 4
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract 4
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract 4
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract 4
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract 4
- 235000006533 astragalus Nutrition 0.000 claims abstract 4
- 229940010454 licorice Drugs 0.000 claims abstract 4
- 210000004233 talus Anatomy 0.000 claims abstract 4
- 238000000605 extraction Methods 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 13
- 239000000341 volatile oil Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000003651 drinking water Substances 0.000 claims description 6
- 235000020188 drinking water Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims 3
- 239000001116 FEMA 4028 Substances 0.000 claims 3
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 3
- 229960004853 betadex Drugs 0.000 claims 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims 2
- 235000017491 Bambusa tulda Nutrition 0.000 claims 2
- 244000082204 Phyllostachys viridis Species 0.000 claims 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims 2
- 239000011425 bamboo Substances 0.000 claims 2
- 235000008216 herbs Nutrition 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 244000205574 Acorus calamus Species 0.000 claims 1
- 235000011297 Brassica napobrassica Nutrition 0.000 claims 1
- 241000219192 Brassica napus subsp. rapifera Species 0.000 claims 1
- 235000011996 Calamus deerratus Nutrition 0.000 claims 1
- 241001107116 Castanospermum australe Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 244000273928 Zingiber officinale Species 0.000 claims 1
- 235000006886 Zingiber officinale Nutrition 0.000 claims 1
- 235000021279 black bean Nutrition 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 235000008397 ginger Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 9
- 208000011580 syndromic disease Diseases 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 8
- 210000004556 brain Anatomy 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 208000026435 phlegm Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 230000003930 cognitive ability Effects 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 210000003792 cranial nerve Anatomy 0.000 abstract 1
- 241000244155 Taenia Species 0.000 description 16
- 230000010354 integration Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 241000628997 Flos Species 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 6
- 239000009636 Huang Qi Substances 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 235000015099 wheat brans Nutrition 0.000 description 4
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 101150060184 ACHE gene Proteins 0.000 description 2
- 241000545442 Radix Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- -1 mixes Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- IAVUBSCVWHLRGE-UXEKTNMQSA-N (6e)-2,5-dihydroxy-6-[(e)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C(C(O)([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C1=O)=O)=C(O)\C1=C(/O)\C=C\C1=CC=C(O)C=C1 IAVUBSCVWHLRGE-UXEKTNMQSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940125682 antidementia agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RKFAZBXYICVSKP-UHFFFAOYSA-N beta- asarone Natural products COC1=CC(OC)=C(C=CC)C=C1OC RKFAZBXYICVSKP-UHFFFAOYSA-N 0.000 description 1
- RKFAZBXYICVSKP-WAYWQWQTSA-N beta-asarone Chemical compound COC1=CC(OC)=C(\C=C/C)C=C1OC RKFAZBXYICVSKP-WAYWQWQTSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- ZZMASNSDVDSYKO-UHFFFAOYSA-N hydroxysafflor yellow A Natural products OCC1OC(C(O)C(O)C1O)C2=C(O)C(O)(C3OC(CO)C(O)C(O)C3O)C(=O)C(=C2O)C(=O)C=Cc4ccc(O)cc4 ZZMASNSDVDSYKO-UHFFFAOYSA-N 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗血管性痴呆的中成药及其制备方法，是由下述重量组份的原料配制而成：熟地15~20份，山萸肉10~15份，黄芪8~12份，丹参12~18份，红花9~15份，川芎9~15份，竹茹6~12份，石菖蒲6~12份，甘草4~10份。本发明的药物具有益气补肾、祛瘀化痰、醒脑开窍的功效，能够改善血管性痴呆患者临床症状，对血管性痴呆患者的中医证候积分、认知能力、日常生活能力和脑神经递质均有改善作用，总有效率达85.4%，治疗血管性痴呆效果可靠，无明显毒副作用，并且生物利用度高，可控性和稳定性好。The invention discloses a Chinese patent medicine for treating vascular dementia and a preparation method thereof, which is prepared from raw materials with the following weight components: 15-20 parts of rehmannia glutinosa, 10-15 parts of cornus, and 8-12 parts of astragalus , 12~18 parts of Salvia miltiorrhiza, 9~15 parts of safflower, 9~15 parts of Chuanxiong, 6~12 parts of Zhuru, 6~12 parts of Shichangpu, and 4~10 parts of licorice. The medicine of the present invention has the effects of nourishing qi and tonifying the kidney, dispelling blood stasis and resolving phlegm, refreshing the brain and resuscitating the brain, can improve the clinical symptoms of patients with vascular dementia, and can improve the TCM syndrome scores, cognitive ability, daily living ability and cranial nerve function of patients with vascular dementia. All the transmitters have improvement effect, the total effective rate reaches 85.4%, the treatment effect of vascular dementia is reliable, there is no obvious side effect, and the bioavailability is high, and the controllability and stability are good.
Description
Technical field
The present invention relates to Chinese medicine technical field, particularly a kind of Chinese patent medicine for the treatment of vascular dementia and preparation method thereof.
Background technology
Vascular dementia (Vascular Dementia, VD) be the brain tissue damage being caused by a series of cerebrovascular diseases and a kind of dementia syndrome producing, being after intelligence fully develops, being caused the result of degeneration by the infringement of apoplexy, is one of main Types of senile dementia.With when anything crops up forgetful, can not be directed, misinterpretation, the mental disorder disease that the poor grade of computing power is principal character, wherein hypomnesis is early stage core symptom [1].Epidemiological study shows, VD sickness rate sharply rose along with the age, and dull-witted high prevalence and sickness rate have brought serious burden to family and society.Along with the development of social senilization, paralytic increases, and VD has become the main Types of China's dementia, and existing patient more than 500 ten thousand people not yet find the antidementia agent of desirable improvement intelligence up to now.Therefore, control VD, the quality of life of reducing sickness rate and improving patient has important social meaning and realistic meaning.
Modern medicine control VD mainly adopts the Comprehensive Treatment of controlling underlying diseases, improving the dementia such as cerebral circulation and brain protection.But because some pathways of drug action is not yet clear and definite, side effect is obvious, late result needs to be evaluated, and expensive, they often are only confined to control the aspects such as underlying diseases, it not plays a role for the pathogenetic each link of VD, thereby be difficult to obtain satisfied prevention effect, so seriously restricted its clinical practice.And tcm clinical control VD toxic and side effects is little, medicine source is abundant, cheap, and the adjusting allomeric function of energy multipath, too many levels, many target spots, improves clinical symptoms, in control VD, has demonstrated unique advantage.Therefore, develop the Chinese patent medicine of a kind of VD for the treatment of, will produce huge economic and social benefit.
Summary of the invention
For the problems referred to above, the object of the invention is just to provide the Chinese patent medicine of the treatment vascular dementia that a kind of curative effect is reliable, toxic and side effects is little, with low cost.
Another object of the present invention provides a kind of preparation method of Chinese patent medicine for the treatment of vascular dementia.
The technical scheme that the present invention addresses the above problem employing is, a kind of Chinese patent medicine for the treatment of vascular dementia is characterized in that being that the raw material Chinese medicine by following weight portion makes:
15 ~ 20 parts, Radix Rehmanniae Preparata, 10 ~ 15 parts of Fructus Corni, 8 ~ 12 parts of the Radixs Astragali, 12 ~ 18 parts of Radix Salviae Miltiorrhizaes, 9 ~ 15 parts, Flos Carthami, 9 ~ 15 parts of Rhizoma Chuanxiongs, 6 ~ 12 parts of Caulis Bambusae In Taenia, 6 ~ 12 parts of Rhizoma Acori Graminei, 4 ~ 10 parts, Radix Glycyrrhizae; Fructus Corni, Rhizoma Acori Graminei and Caulis Bambusae In Taenia in said ratio prescription carries out the following method process of preparing Chinese medicine in use: Fructus Corni wine steams method; Rhizoma Acori Graminei is fried method with wheat bran; Caulis Bambusae In Taenia processed with Rhizoma Zingiberis Recens.
More preferably:
18 parts, Radix Rehmanniae Preparata, 12 parts of Fructus Corni, 10 parts of the Radixs Astragali, 15 parts of Radix Salviae Miltiorrhizaes, 12 parts, Flos Carthami, 12 parts of Rhizoma Chuanxiongs, 10 parts of Caulis Bambusae In Taenia, 9 parts of Rhizoma Acori Graminei, 6 parts, Radix Glycyrrhizae.
A preparation method for the Chinese patent medicine for the treatment of vascular dementia, is characterized in that preparing in the steps below:
1. get Rhizoma Acori Graminei, Rhizoma Chuanxiong two taste medicines, adopt supercritical CO
2method extraction volatile oil, gets two taste medicinal powders by above-mentioned dose, drops in extraction kettle, and separating still pressure is 5.5～6.0MPa, and extraction kettle pressure is 15MPa, 30 ℃ of extraction kettle temperature, and separating still temperature is identical with extraction kettle, regulates CO
2flow is 25.00L/h, and when extraction kettle pressure reaches 15MPa, first static extracting 30min, then dynamic extraction 3h, obtain volatile oil, and medicinal residues are standby;
2. by step 1 Chinese medicine slag and Radix Rehmanniae Preparata, Fructus Corni, the Radix Astragali, Radix Salviae Miltiorrhizae, Flos Carthami, Caulis Bambusae In Taenia, Radix Glycyrrhizae, merge to drop in extraction pot and carry out water extraction, add 6 ~ 9 times of amount drinking waters, infiltrate 1h, then heated and boiled is extracted 2h, extracting solution is put into concentration tank through filter screen, add 6 times of amount drinking waters again and extract 2h, secondary raffinate is also put into concentration tank through filter screen, and then concentrating under reduced pressure becomes cream, put in cleaner, standby;
3. take beta-schardinger dextrin-, add distilled water, its mass ratio is beta-schardinger dextrin-: distilled water=1:25, is heated to boiling, dissolve, then be cooled to 45 ℃, get volatile oil prepared by step 1, in mass ratio beta-schardinger dextrin-: volatile oil=6:1 adds, constant temperature stirs 1h, cold preservation 24h, filters, and precipitate is drying to obtain clathrate below in 50 ℃;
4. the clathrate of being prepared by step 3 adds in ointment prepared by step 2, then with sucrose, mixes, and granulates;
5. above-mentioned granule is dried (60 ± 5 ℃), then always mixed, granulate, subpackage and get final product.
The using method of this granule is: per day for adults 3 times, each 10g, one after each meal.
Medicine of the present invention is being studied successive dynasties document and is summing up on the basis of clinical practice for many years, using drugs to form a prescription, wherein the special beneficial essence of Radix Rehmanniae Preparata merit is filled out marrow, nourishing YIN and supplementing blood, the function with anti-cerebral ischemia damnification and raising learning and memory, can reduce model mouse cerebral tissue MDA content and AchE activity, increases Ach content in brain, improve central cholinergic system function, thereby produce nootropic effect; Fructus Corni is the good merchantable brand of benefiting essence-blood, invigorating the liver and kidney, and they are different extracts compositions and can improve the ability of learning and memory of VD Mus due to chronic cerebral ischemia, suppresses AchE activity of hippocampus activity, the effect of performance neuroprotective unit; The Radix Astragali can strongly invigorating primordial QI, the Fructus Alpiniae Oxyphyllae of calming the nerves, thereby astragaloside can improve ability of learning and memory by the synaptic density that increases Hippocampus; Flos Carthami has the merit of blood circulation promoting and blood stasis dispelling, and its main component Carthamus yellow, S-A Hydroxysafflor yellow A have obvious protective effect to focal cerebral ischemia, can improve rats with cerebral ischemia behavioristics's symptom, alleviate ischemia and reduce histo pathological change due to its cerebral infarct size; Rhizoma Chuanxiong is the gas medicine in blood, there is promoting flow of QI and blood, the merit of wind-expelling pain-stopping, its main extract ligustrazine (TMP) easily sees through blood brain barrier, can significantly alleviate leukocyte and the vascular endothelial cell adhesion of cerebral ischemia reperfusion injury, and suppress the expression of inflammatory cell release proinflammatory factor (as TNF-ɑ), remove free radical, the generation of lowering NO, alleviates the inflammatory reaction of peripheral tissues; Radix Salviae Miltiorrhizae has the merit of removing heat from blood and promoting blood circulation, nourishing blood to tranquillize the mind, and its effective ingredient TANSHINONES can anti-cerebral ischemia, cerebral anoxia, has the effects such as the microcirculation of improvement, and the danshensu in its water-soluble bolt composition significantly anti-platelet aggregation, antithrombotic forms, promotes fibrinolytic activeness; Rhizoma Acori Graminei have eliminate the phlegm have one's ideas straightened out, the merit of removing dampness to restore normal function of the stomach, the mind calming and mentality promoting, its total volatile oil, the decoct that deoils, beta-Asarone, a-asaricin all have improvement in various degree to various dysmnesia models; The effect that Caulis Bambusae In Taenia has clearing heat and relieving fidgetness, eliminates the phlegm and have one's ideas straightened out, its extract can improve learning and memory function; Radix Glycyrrhizae QI invigorating and in, coordinating the actions of various ingredients in a prescription.Said medicine combination makes each efficacy of drugs produce synergism, thereby plays the merit of vital energy benefiting and the kidney invigorating, dissipating phlegm and removing blood stasis, consciousness-restoring and orifice-opening.
Abundant raw materials of the present invention, preparation method is simple, cheap, patient's taking convenience, clinical efficacy is remarkable, and bioavailability is high, and controllability and good stability are the innovations on treatment vascular dementia medicine.
The specific embodiment
Below in conjunction with embodiment, the specific embodiment of the present invention is elaborated.
Embodiment 1
Treat a Chinese patent medicine for vascular dementia, by the raw material Chinese medicine of following weight portion, made:
Radix Rehmanniae Preparata 18g, Fructus Corni 12g, Radix Astragali 9g, Radix Salviae Miltiorrhizae 15g, Flos Carthami 12g, Rhizoma Chuanxiong 12g, Caulis Bambusae In Taenia 6g, Rhizoma Acori Graminei 9g, Radix Glycyrrhizae 6g.Fructus Corni, Rhizoma Acori Graminei and Caulis Bambusae In Taenia in said ratio prescription carries out the following method process of preparing Chinese medicine in use: Fructus Corni wine steams method; Rhizoma Acori Graminei is fried method with wheat bran; Caulis Bambusae In Taenia processed with Rhizoma Zingiberis Recens.
Above-mentioned raw materials Chinese medicine is prepared as follows:
1. get Rhizoma Acori Graminei, Rhizoma Chuanxiong two taste medicines, adopt supercritical CO
2method extraction volatile oil, gets two taste medicinal powders by above-mentioned dose, drops in extraction kettle, and separating still pressure is 5.5～6.0MPa, and extraction kettle pressure is 15MPa, 30 ℃ of extraction kettle temperature, and separating still temperature is identical with extraction kettle, regulates CO
2flow is 25.00L/h, and when extraction kettle pressure reaches 15MPa, first static extracting 30min, then dynamic extraction 3h, obtain volatile oil, and medicinal residues are standby;
2. step 1 Chinese medicine slag and Radix Rehmanniae Preparata, Fructus Corni, the Radix Astragali, Radix Salviae Miltiorrhizae, Flos Carthami, Caulis Bambusae In Taenia, Radix Glycyrrhizae merging are dropped in extraction pot and carry out water extraction, add 6 ~ 9 times of amount drinking waters, infiltrate 1h, heated and boiled is extracted 2h again, and extracting solution is put into concentration tank through filter screen, then adds 6 times of amount drinking waters extraction 2h, secondary raffinate is also put into concentration tank through filter screen, then concentrating under reduced pressure becomes cream, puts in cleaner, standby;
3. take beta-schardinger dextrin-, add distilled water, its mass ratio is beta-schardinger dextrin-: distilled water=1:25, is heated to boiling, dissolve, then be cooled to 45 ℃, get volatile oil prepared by step 1, in mass ratio beta-schardinger dextrin-: volatile oil=6:1 adds, constant temperature stirs 1h, cold preservation 24h, filters, and precipitate is drying to obtain clathrate below in 50 ℃;
4. the clathrate of being prepared by step 3 adds in ointment prepared by step 2, then with sucrose, mixes, and granulates;
5. above-mentioned granule is dried (60 ± 5 ℃), then always mixed, granulate, subpackage and get final product.
Embodiment 2
Treat a Chinese patent medicine for vascular dementia, by the raw material Chinese medicine of following weight portion, made: Radix Rehmanniae Preparata 20g, Fructus Corni 15g, Radix Astragali 10g, Radix Salviae Miltiorrhizae 12g, Flos Carthami 15g, Rhizoma Chuanxiong 15g, Caulis Bambusae In Taenia 9g, Rhizoma Acori Graminei 10g, Radix Glycyrrhizae 9g.Fructus Corni, Rhizoma Acori Graminei and Caulis Bambusae In Taenia in said ratio prescription carries out the following method process of preparing Chinese medicine in use: Fructus Corni wine steams method; Rhizoma Acori Graminei is fried method with wheat bran; Caulis Bambusae In Taenia processed with Rhizoma Zingiberis Recens.
Preparation method: with embodiment 1.
Embodiment 3
Treat a Chinese patent medicine for vascular dementia, by the raw material Chinese medicine of following weight portion, made: Radix Rehmanniae Preparata 15g, Fructus Corni 10g, Radix Astragali 8g, Radix Salviae Miltiorrhizae 10g, Flos Carthami 9g, Rhizoma Chuanxiong 12g, Caulis Bambusae In Taenia 6g, Rhizoma Acori Graminei 9g, Radix Glycyrrhizae 5g.Fructus Corni, Rhizoma Acori Graminei and Caulis Bambusae In Taenia in said ratio prescription carries out the following method process of preparing Chinese medicine in use: Fructus Corni wine steams method; Rhizoma Acori Graminei is fried method with wheat bran; Caulis Bambusae In Taenia processed with Rhizoma Zingiberis Recens.
Preparation method: with embodiment 1.
Medicine major function of the present invention and treatment disease:
1. major function: vital energy benefiting and the kidney invigorating, eliminate stagnation and dissolve phlegm, consciousness-restoring and orifice-opening.
2. treatment disease: vascular dementia, Chinese medical discrimination is shenxu-tanyu type.
3. usage and consumption: per day for adults 3 times, each 10g, one after each meal.
The clinical observation of medicine of the present invention:
Use Chinese medicine granules treatment vascular dementia of the present invention, patient's taking convenience, good effect, has no side effect, and concrete relevant clinical data of the present invention is as follows:
1. patient clinical data
(1) physical data
Choose VD patient's 70 examples that Affiliated Hospital of Nanyang Institute of Technology in year March in May, 2010 to 2012, Nanyang institute of traditional Chinese medicine meet inclusive criteria, adopt SPSS14.0 statistical package that treatment group and matched group are produced to random coded in the ratio of 5: 2 by method of randomization, according to this random number, by testing irrelevant personnel with this, medicine encoded and preserve random table, during clinical research, by the medicine numbering of distributing and the selected order of case, using successively.Wherein treatment group 50 examples, man's 32 examples, female's 18 examples, matched group 20 examples, man's 14 examples, female's 6 examples, rejecting data is incomplete, 4 examples such as do not take medicine in accordance with regulations, meet totally 66 examples that research requires, wherein treatment group 47 examples, matched group 19 examples, two groups of patients have comparability at equal not statistically significants of aspect difference (P > 0.05) such as sex, age, the cerebrovascular course of disease, the dull-witted course of disease, schooling, common merging diseases.
(2) diagnostic criteria
2. the dialectical standard of traditional Chinese medical science shenxu-tanyu type is with reference to " vascular dementia diagnosis, differentiation of symptoms and signs for classification of syndrome and efficacy assessment standard " (tentative program) of < < new Chinese medicine guideline of clinical investigations (try) > > in 2002 and the formulation of neurological branch of China Association of Traditional Chinese Medicine.
3. inclusive criteria: a, meet VD diagnostic criteria; B, age 50-80 year; C, in Cerebral Vascular Disease 3 months, occur dull-wittedly, and dementia symptom continues more than 3 months d, meets the dialectical standard of traditional Chinese medical science shenxu-tanyu type; E, stop using western medicines in treatment at least January.
4. exclusion standard: a, be associated with severe cardiac, lung, renal dysfunction, disease of hematopoietic system, and other Organ dysfunctions person; Dementia due to b, other sacred disease and systemic disease; C, merging depression person; The Chinese and western drugs person of d, recent application other treatment dementia.
2. method
(1) Therapeutic Method
Matched group: give hydergine tablet oral (Tianjin Hua Jin pharmaceutical factory produces, 1mg/ sheet), 2 pieces/times, every day 3 times.Treatment group: give Chinese medicine granules of the present invention, every day 3 times, each 10g.Decocting divides sooner or later each 1 clothes.Two groups of equal medications 2 months, two groups during treating, except with hypertension, diabetes or be associated with and infect class Disease and can add depressor, antidiabetic drug or anti-infective beyond the region of objective existence, other drug is stopped using without exception.
(2) observation index and method
MMSE integration: evaluation cognitive competence and disturbance of intelligence are improved situation, changes and judges its curative effect according to the integrated value before and after its treatment, efficacy determination method and standard foundation, the dialectical and curative effect determinate standard of the diagnosis of vascular dementia;
Evaluation of activities of daily living: adopt < < activity of daily living (ADL) scale > >, comprise instrumental activity of daily living (IADL) and two parts of corporality activity of daily living (PSMS), the activity of daily living for the treatment of Patients Before And After is tested and assessed;
Tcm syndrome integration evaluation: evaluate two groups of patient treatments front and back tcm syndrome integrations;
In brain, neurotransmitter is measured: mainly measure acetylcholine and monoamine neurotransmitter inhibin (INH), excitatory transmitter 5-hydroxy tryptamine (5-HT), dopamine (DA), norepinephrine (NE), acetylcholine (ACH) etc., each detection 1 time before and after treatment;
Safety indexes: untoward reaction during basic vital signs, medication.
(3) criterion of therapeutical effect
MMSE curative effect determinate standard: according to integration before and after scale treatment, be divided into effective to treat rear MMSE total score increase >=5; Increasing by 4～2 is divided into effectively; Increase≤2 points or drop to invalid.20 evaluation criterias of ADL viability: be divided into effective to treat rear ADL total score decline >=6; Decline 5～3 is divided into effectively; 3 points of decline < or ascensionist are invalid.
Evaluation of activities of daily living standard: Barthel scoring method by ADL ability be divided into good, in, differ from 3 grades: be greater than 60 be divided into good; 60～41 are divided into, and have dysfunction, slightly rely on; Be less than 40 and be divided into poorly, rely on more obviously or completely and rely on.
(4) safety evaluatio
1 grade is safety, without any untoward reaction; 2 grades is safer, if any untoward reaction, does not need to do any processing and can continue administration; 3 grades is to have safety issue, has moderate untoward reaction, after processing, can continue administration; 4 grades is to end to observe because of untoward reaction.
(5) statistical method mean ± standard deviation for data (
± s) represent.Adopt SPSS14.0 statistical package statistical analysis, enumeration data adopts χ
2check, measurement data adopts t check.
3. result
(1) two groups of cognitive ability curative effect comparison
Treatment group 48 examples, effective 15 examples, effective 26 examples, invalid 7 examples, total effective rate 85.42%, matched group 20 examples, effective 5 examples, effective 11 examples, invalid 4 examples, 80%, two group of comparing difference not statistically significant P < 0.05 of total effective rate
MMSE integral contrast before and after (2) two groups of treatments
Table 1 shows, after treatment group treatment, calculating and total mark are all obviously improved (P < 0.05) compared with matched group, two groups of orientations, memorize and language integral contrast difference not statistically significant (P < 0.05), treatment group is except language integration, all other and total mark are all obviously improved (P < 0.05 or P < 0.01) before treatment, the directed integration of matched group and total mark are treated obviously (P < 0.05) of front improvement, other every integrations and the front comparing difference not statistically significant (P < 0.05) for the treatment of.
MMSE integral contrast before and after table 1 liang group VD patient treatment (point,
± s)
Note: this group and the front relatively * P for the treatment of < 0.05, * * P < 0.01; With comparison Δ P < 0.05 after treatment of control group.Activity of daily living and tcm syndrome integral contrast before and after (3) two groups of treatments
Table 2 shows, after treatment group treatment, PSMS integration improves obviously (P < 0.05) compared with matched group, two groups of ADL, IADL integration statistical discrepancy not statistically significant (P < 0.05), treatment group ADL, IADL integration are treated obviously (P < 0.05) of front improvement, treatment group PSMS integration and control group A DL, IADL, PSMS integration and the front comparing difference not statistically significant (P < 0.05) for the treatment of.
After two groups of treatments, tcm syndrome integration all obviously improves (P < 0.05 or P < 0.01) before treatment, and after treatment group treatment, tcm syndrome integration is obviously better than matched group (P < 0.05).
Activity of daily living and tcm syndrome integral contrast before and after table 2 liang group VD patient treatment (point,
± s)
Note: this group and the front relatively * P for the treatment of < 0.05, * * P < 0.01; With comparison Δ P < 0.05 after treatment of control group.
(4) full brain neurotransmitter SET value situation of change comparison
Table 3 shows that the rear ACH for the treatment of group treatment and NE obviously improve (P < 0.05) compared with matched group, after treatment group treatment, ACH, DA, NE obviously improve (P < 0.05 or P < 0.01) before treating, and comparing difference not statistically significant (P < 0.05) before NH, 5-HT and treatment, all kinds of mediators and the front equal not statistically significant of comparing difference (P < 0.05) for the treatment of after treatment of control group.
A full brain neurotransmitter (SET value) comparison before and after table 3 liang group VD patient treatment (
± s)
Note: this group and the front relatively * P for the treatment of < 0.05, * * P < 0.01; With comparison Δ P < 0.05 after treatment of control group, Δ Δ P < 0.05
(3) the routine VD patient safety of safety evaluatio treatment group 48 index shows no obvious abnormalities.
4. conclusion
Chinese medicine granules treatment vascular dementia of the present invention is evident in efficacy, and without obvious toxic-side effects, patient compliance is good, is a kind of effective Therapeutic Method.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310734509.4A CN103721102B (en) | 2013-12-27 | 2013-12-27 | It is a kind of to treat Chinese patent drug of vascular dementia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310734509.4A CN103721102B (en) | 2013-12-27 | 2013-12-27 | It is a kind of to treat Chinese patent drug of vascular dementia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103721102A true CN103721102A (en) | 2014-04-16 |
| CN103721102B CN103721102B (en) | 2017-06-23 |
Family
ID=50445563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310734509.4A Expired - Fee Related CN103721102B (en) | 2013-12-27 | 2013-12-27 | It is a kind of to treat Chinese patent drug of vascular dementia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103721102B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587191A (en) * | 2015-02-02 | 2015-05-06 | 张成杰 | Traditional Chinese medicine for treating vascular dementia |
| CN104983962A (en) * | 2015-06-30 | 2015-10-21 | 虞志秋 | Traditional Chinese medicine capsules for preventing and treating senile dementia |
| CN104983961A (en) * | 2015-06-30 | 2015-10-21 | 虞志秋 | Traditional Chinese medicine decoction for preventing and treating senile dementia |
| CN104984110A (en) * | 2015-06-30 | 2015-10-21 | 虞志秋 | Traditional Chinese medicine decoction for preventing and treating presenile dementia |
| CN105012611A (en) * | 2015-08-20 | 2015-11-04 | 金思思 | Medicine for treating Alzheimer disease |
| CN105031325A (en) * | 2015-06-30 | 2015-11-11 | 虞志秋 | Chinese herbal capsule for preventing and curing presenile dementia |
| CN107982442A (en) * | 2017-12-15 | 2018-05-04 | 兖矿集团有限公司总医院 | A kind of kidney tonifying resolving sputum, the medicament composing prescription of opening the orifice and activating blood circulation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0911333A1 (en) * | 1997-10-24 | 1999-04-28 | Pfizer Inc. | Pyrazolo[4,3-d]pyrimidine derivatives and pharmaceutical compositions containing them |
| CN1386511A (en) * | 2001-05-22 | 2002-12-25 | 周亚滨 | Medicine for preventing and treating senile dementia |
| CN1438005A (en) * | 2003-03-14 | 2003-08-27 | 山东中医药大学 | Medicine for vascular denmentia disease and preparation method |
-
2013
- 2013-12-27 CN CN201310734509.4A patent/CN103721102B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0911333A1 (en) * | 1997-10-24 | 1999-04-28 | Pfizer Inc. | Pyrazolo[4,3-d]pyrimidine derivatives and pharmaceutical compositions containing them |
| CN1386511A (en) * | 2001-05-22 | 2002-12-25 | 周亚滨 | Medicine for preventing and treating senile dementia |
| CN1438005A (en) * | 2003-03-14 | 2003-08-27 | 山东中医药大学 | Medicine for vascular denmentia disease and preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 张利平: "通窍健脑汤治疗血管性痴呆35例", 《中医研究》 * |
| 范青生: "《保健食品工艺学》", 30 November 2006, 中国医药科技出版社 * |
| 赵静等: "多奈哌齐治疗老年血管性痴呆的系统评价", 《中国循证医学杂志》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587191A (en) * | 2015-02-02 | 2015-05-06 | 张成杰 | Traditional Chinese medicine for treating vascular dementia |
| CN104983962A (en) * | 2015-06-30 | 2015-10-21 | 虞志秋 | Traditional Chinese medicine capsules for preventing and treating senile dementia |
| CN104983961A (en) * | 2015-06-30 | 2015-10-21 | 虞志秋 | Traditional Chinese medicine decoction for preventing and treating senile dementia |
| CN104984110A (en) * | 2015-06-30 | 2015-10-21 | 虞志秋 | Traditional Chinese medicine decoction for preventing and treating presenile dementia |
| CN105031325A (en) * | 2015-06-30 | 2015-11-11 | 虞志秋 | Chinese herbal capsule for preventing and curing presenile dementia |
| CN105012611A (en) * | 2015-08-20 | 2015-11-04 | 金思思 | Medicine for treating Alzheimer disease |
| CN107982442A (en) * | 2017-12-15 | 2018-05-04 | 兖矿集团有限公司总医院 | A kind of kidney tonifying resolving sputum, the medicament composing prescription of opening the orifice and activating blood circulation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103721102B (en) | 2017-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721102A (en) | Chinese patent medicine for treating vascular dementia and preparation method thereof | |
| CN111202827A (en) | Chinese medicine for preventing influenza, SARS, bird flu and new coronary pneumonia | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN101366903B (en) | Traditional Chinese medicine composition for treating climacteric syndrome | |
| CN102188682B (en) | Chinese medicinal composition for treating biliary calculus and preparation method thereof | |
| CN103446445B (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN103142894B (en) | Traditional Chinese medicine composition for rehabilitation of tumor patients after radiotherapy and chemotherapy, and preparation method thereof | |
| CN102000319B (en) | A kind of preparation method of Nuanwei Shule tablet | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN103191293B (en) | Sub-health-preventive drug composition and preparation method thereof | |
| CN107375829A (en) | Treat the Chinese medicine composition of Post-apoplectic and its preparation method of preparation | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof | |
| CN104435079A (en) | Traditional Chinese medicinal composition for treating gout | |
| CN109771632A (en) | A pharmaceutical composition for the treatment of chronic obstructive pulmonary disease in stable phase and its preparation method and use | |
| CN117045764B (en) | Traditional Chinese medicine composition for treating type II diabetes and preparation method thereof | |
| CN104288375B (en) | A kind of pharmaceutical composition and its new application for treating vascular dementia | |
| CN109908294B (en) | Pharmaceutical composition for treating stable stage of bronchiectasis and preparation method and application thereof | |
| CN102416147B (en) | Medicinal composition for treating mania of patients abstained from drugs | |
| CN103919990B (en) | Traditional Chinese medicine composition, as well as preparation method and applications thereof | |
| CN107519370B (en) | Compound preparation for treating non-allergic purpura caused by deficiency of spleen and kidney and preparation method thereof | |
| CN107007721B (en) | Traditional Chinese medicine compound preparation for treating anemia caused by qi deficiency of spleen and kidney and preparation method | |
| CN104383236A (en) | Traditional Chinese medicine composition for treating pyrophlegm internal disturbance syndrome type hyperthyroidism | |
| CN116115726A (en) | Traditional Chinese medicine composition for treating gastroesophageal reflux cough and application thereof | |
| CN104826019A (en) | Traditional Chinese medicine composition for treating hepatitis B with hepatic fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Hu Jiulue Inventor after: Bian Hua Inventor after: Du Qingmian Inventor after: Zhang Yanying Inventor after: Zhang Lifang Inventor after: Ma Changde Inventor after: Lu Peng Inventor before: Hu Jiulue Inventor before: Bian Hua Inventor before: Shi Maguanghan Inventor before: Zhang Yanying Inventor before: Zhang Lifang Inventor before: Ma Changde Inventor before: Lu Peng |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170623 Termination date: 20211227 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |